Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORM: Mosunetuzumab vs Rituximab in NLPHL
NCT05886036Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2024
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of mosunetuzumab in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 2 years. Started Jan 2024; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
Beyond the preview
Go deeper on NCT05886036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886036.